Condition (MeSH)
Mast-Cell Sarcoma
ClinicalTrials.gov lists 2 trials for Mast-Cell Sarcoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Mast-Cell Sarcoma itself; the rest are tagged with a narrower condition beneath it.
When did Mast-Cell Sarcoma trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2011 | 1 |
| 2010 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mast-Cell Sarcoma trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 1 |
| Not applicable | 1 |
How many Mast-Cell Sarcoma trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Terminated | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which serious adverse events do Mast-Cell Sarcoma trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile Neutropenia | 2 | 1 |
| Platelet count decrease | 2 | 1 |
| Intracranial hemorrhage | 1 | 1 |
| Neutrophil count decrease | 1 | 1 |
Which publications cover Mast-Cell Sarcoma? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. | The Journal of experimental medicine | 1983 | Yes |
| Diagnostic criteria and classification of mastocytosis: a consensus proposal. | Leukemia research | 2001 | No |
| Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. | Nature medicine | 1998 | No |
| Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. | Cancer chemotherapy and pharmacology | 1989 | No |
| Secretion of pyruvate. An antioxidant defense of mammalian cells. | The Journal of experimental medicine | 1987 | No |
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Mast cell sarcoma | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Mast cell sarcoma | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Mast cell sarcoma | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Mast cell sarcoma | 66661 | Exact | Orphadata Science knowledge files, Product 1 |
| Mast cell sarcoma | 66661 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.